ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ERAS vs TVTX // EV/EBITDA & P/E VALUATION

Erasca Inc. (NASDAQ) VS. Travere Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ERAS 2 — TVTX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ERAS VS. TVTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ERAS TVTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -13.00% -22.00 TVTX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -1.82% 0.33% -2.15 TVTX /fcf-yield <GO>
Operating Margin — -12.80% — TIE /operating-margins <GO>
Net Profit Margin — -5.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 110.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.44 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 TVTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 35.8 +9.50 ERAS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.02B $4.75B $269.3M ERAS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ERAS REV TVTX REV ERAS GROSS % TVTX GROSS % ERAS FCF TVTX FCF
FY 2025 $394.5M $490.7M — 97.9% -$95.6M $15.7M
FY 2024 $502.8M $233.2M — 96.7% -$109.5M -$248.0M
FY 2023 $396.3M $145.2M — — -$101.2M -$286.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ERAS // BETA —
TVTX // BETA 1.08